TABLE 3

Biodistribution in Tumored Mice 3 Hours After Administration of ^99mTc-MORF (Study 2)

Organ	Study			Control I	Control II	P value*
	¹¹¹In	^99mTc [1]	^99mTc [2]	^99mTc [3]	[1] vs. [2]	[1] vs. [3]
Liver	38.3 ± 3.2	0.77 ± 0.40	0.32 ± 0.03	0.26 ± 0.01	0.052	0.048
Heart	0.51 ± 0.02	0.07 ± 0.00	0.07 ± 0.01	0.06 ± 0.01	0.183	0.215
Kidney	2.41 ± 0.67	13.2 ± 6.3	15.7 ± 3.9	12.2 ± 5.5	0.675	0.480
Lung	0.27 ± 0.00	0.16 ± 0.00	0.27 ± 0.01	0.14 ± 0.02	0.012	0.117
Spleen	8.30 ± 1.6	0.35 ± 0.04	0.62 ± 0.19	0.13 ± 0.01	0.110	0.001
Muscle	0.10 ± 0.02	0.05 ± 0.01	0.14 ± 0.06	0.13 ± 0.08	0.048	0.059
Tumor	0.52 ± 0.02	0.50 ± 0.10	0.26 ± 0.05	0.14 ± 0.02	0.043	0.001
Blood	0.05 ± 0.01	0.12 ± 0.01	0.12 ± 0.00	0.08 ± 0.00	0.510	0.002

Study animals (amplification targeting) received unlabeled antibody 74 h earlier and ¹¹¹In-labeled polymer 44 h earlier (Fig. 1). Control I animals did not receive antibody and received only polymer. Control II animals received neither antibody nor polymer.
↵* Student t test for significance, P < 0.05 (statistically significant values are underlined).
Data are expressed as average %ID/g ± SD; n = 4.